TECH Bio-Techne Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECH

Price (delayed)

$72.145

Market cap

$11.3B

P/E Ratio

101.61

Dividend/share

$0.32

EPS

$0.71

Enterprise value

$11.38B

?
Relative Growth: Rel. Growth: 38
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 59

Contact: David Clair, Senior Director, Corporate Development [email protected] 612-656-4416 SOURCE Bio-Techne Corporation Related Links https://www.bio-techne.com/

Highlights
Bio-Techne's debt has decreased by 31% YoY and by 17% QoQ
The quick ratio has increased by 24% year-on-year and by 9% since the previous quarter
TECH's EPS is up by 37% since the previous quarter but it is down by 14% year-on-year
The net income has increased by 35% from the previous quarter but it has decreased by 17% YoY
TECH's P/E is 42% above its 5-year quarterly average of 71.5
Sector: Healthcare
Industry: Biotechnology
Website: http://www.bio-techne.com
Peers: TMO DHR QGEN BDX

Key stats

What are the main financial stats of TECH

TECH stock price

How has the Bio-Techne stock price performed over time
Intraday
0.08%
1 week
0.73%
1 month
1.86%
1 year
31.44%
YTD
22.67%
QTD
2.12%

Financial performance

How have Bio-Techne's revenue and profit performed over time
Revenue
$1.21B
Gross profit
$786.49M
Operating income
$153.75M
Net income
$109.56M
Gross margin
65%
Net margin
9%
The net income has increased by 35% from the previous quarter but it has decreased by 17% YoY
Bio-Techne's net margin has increased by 34% QoQ but it has decreased by 17% YoY
Bio-Techne's operating margin has increased by 32% QoQ but it has decreased by 11% YoY
The company's operating income rose by 31% QoQ but it fell by 11% YoY

Price vs fundamentals

How does TECH's price correlate with its fundamentals

Growth

What is Bio-Techne's growth rate over time

Valuation

What is Bio-Techne stock price valuation
TECH P/E details
P/E
101.61
P/B
5.41
P/S
9.31
EV/EBIT
73.09
EV/EBITDA
44.44
EV/Sales
9.4
TECH's P/E is 42% above its 5-year quarterly average of 71.5
TECH's EPS is up by 37% since the previous quarter but it is down by 14% year-on-year
The stock's price to book (P/B) is 26% more than its last 4 quarters average of 4.3 but 17% less than its 5-year quarterly average of 6.5
Bio-Techne's equity has increased by 3.7% from the previous quarter and by 3.3% YoY
The price to sales (P/S) is 33% higher than the last 4 quarters average of 7.0 but 14% lower than the 5-year quarterly average of 10.8

Efficiency

How efficient is Bio-Techne business performance
TECH's return on assets is up by 34% since the previous quarter but it is down by 12% year-on-year
Bio-Techne's return on equity has increased by 34% QoQ but it has decreased by 13% YoY
Bio-Techne's ROIC has increased by 31% from the previous quarter but it has decreased by 8% YoY
TECH's return on sales is up by 28% since the previous quarter but it is down by 13% year-on-year

Dividends

What is TECH's dividend history
Dividend details
DPS
$0.32
Dividend yield
0.44%
Payout ratio
45.1%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Bio-Techne financials performed over time
Bio-Techne's total liabilities has decreased by 26% YoY and by 9% QoQ
The quick ratio has increased by 24% year-on-year and by 9% since the previous quarter
Bio-Techne's debt is 86% lower than its equity
TECH's debt to equity is down by 33% year-on-year and by 18% since the previous quarter
Bio-Techne's debt has decreased by 31% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.